CSIMarket
 


Frequency Therapeutics Inc   (FREQ)
Other Ticker:  
 

Frequency Therapeutics Inc 's Total Debt to Equity

FREQ's quarterly Total Debt to Equity and Total Debt, Equity growth




FREQ Total Debt to Equity (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Change -44.28 % -42.27 % -36.49 % -32.04 % -26.29 %
Y / Y Total Debt Change 0 % 0 % 0 % 0 % -
Total Debt to Equity MRQ 0.18 0.16 0.13 0.11 0.1
Overall Ranking # # # # #
Seq. Equity Change -14.48 % -14.93 % -13.88 % -11.07 % -11.4 %
Seq. Total Debt Change 0 % 0 % 0 % 0 % 0 %



Total Debt to Equity third quarter 2022 Comment
In Spite of the debt repayement of 0%, in III. Quarter ,Total Debt to Equity detoriated to 0.18, above company's average Total Debt to Equity.

Within Major Pharmaceutical Preparations industry Frequency Therapeutics Inc achieved lowest Total Debt to Equity. While total ranking remained unchanged compare to previous quarter at no. .

Explain Debt to Equity Ratio?
Where is FREQ most successful ?
Total Debt to Equity FREQ on the trailing twelve month basis
Total Debt to Equity third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Total Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Frequency Therapeutics Inc 's Equity $ 82 Millions Visit FREQ's Balance sheet
Frequency Therapeutics Inc 's Total Debt $ 15 Millions Visit FREQ's Balance sheet
Source of FREQ's Sales Visit FREQ's Sales by Geography


Cumulative Frequency Therapeutics Inc 's Total Debt to Equity

FREQ's Total Debt to Equity for the trailling 12 Months

FREQ Total Debt to Equity

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity TTM Growth -44.28 % -42.27 % -36.49 % -32.04 % -26.29 %
Y / Y Total Debt TTM Growth 0 % 0 % 0 % 0 % -
Total Debt to Equity TTM 0.14 0.12 0.11 0.1 0.09
Total Ranking TTM # 770 # 909 # 478 # 108 # 153
Seq. Equity TTM Growth -14.48 % -14.93 % -13.88 % -11.07 % -11.4 %
Seq. Total Debt TTM Growth 0 % 0 % 0 % 0 % 0 %


TTM Total Debt to Equity Comment
On the trailing twelve months basis Despite of the debt repayement of 0% in III. Quarter, Total Debt to Equity improved to 0.14, above Frequency Therapeutics Inc 's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 51 other companies have achieved lower Total Debt to Equity than Frequency Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. 770.

Explain Debt to Equity Ratio?
Where is FREQ most successful ?
Total Debt to Equity FREQ on the trailing twelve month basis

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 52
Healthcare Sector # 152
Within the Market # 770


TTM Total Debt to Equity Statistics
High Average Low
0.04 0.02 0
(Sep 30 2022)   (Dec 31 2021)




Companies with similar Total Debt to Equity in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Total Debt to EquitySep 30 2022 MRQ Total DebtSep 30 2022 MRQ Equity
Pds Biotechnology Corp  0.49 $ 22.910  Millions$ 47.059  Millions
Supernus Pharmaceuticals inc   0.47 $ 401.438  Millions$ 852.798  Millions
Geron Corp  0.47 $ 50.758  Millions$ 108.172  Millions
Cumberland Pharmaceuticals Inc   0.46 $ 17.700  Millions$ 38.491  Millions
Corbus Pharmaceuticals Holdings Inc   0.46 $ 19.269  Millions$ 41.946  Millions
Ibio inc   0.46 $ 22.201  Millions$ 48.368  Millions
Abbott Laboratories  0.46 $ 16,414.000  Millions$ 35,884.000  Millions
Sigilon Therapeutics Inc   0.46 $ 20.288  Millions$ 44.410  Millions
Dynavax Technologies Corporation  0.44 $ 221.303  Millions$ 500.576  Millions
Arcturus Therapeutics Holdings Inc   0.41 $ 59.740  Millions$ 145.667  Millions
Ardelyx inc   0.40 $ 26.541  Millions$ 66.861  Millions
Verastem Inc   0.39 $ 24.667  Millions$ 62.873  Millions
Metacrine Inc   0.37 $ 13.788  Millions$ 37.065  Millions
Equillium Inc   0.37 $ 10.330  Millions$ 28.160  Millions
Eyenovia inc   0.36 $ 7.229  Millions$ 20.329  Millions
Abvc Biopharma Inc   0.33 $ 1.866  Millions$ 5.693  Millions
Scpharmaceuticals Inc   0.32 $ 9.880  Millions$ 31.110  Millions
Syros Pharmaceuticals Inc   0.31 $ 40.514  Millions$ 129.171  Millions
Medavail Holdings Inc   0.31 $ 9.751  Millions$ 31.306  Millions
Selecta Biosciences Inc  0.31 $ 26.094  Millions$ 84.907  Millions
Apellis Pharmaceuticals Inc   0.30 $ 92.663  Millions$ 307.416  Millions
Acelrx Pharmaceuticals Inc  0.29 $ 7.886  Millions$ 27.226  Millions
Iterum Therapeutics Plc  0.29 $ 9.298  Millions$ 32.549  Millions
Organogenesis Holdings Inc   0.28 $ 72.604  Millions$ 256.328  Millions
Alkermes Plc   0.28 $ 293.904  Millions$ 1,042.854  Millions
Mersana Therapeutics inc   0.28 $ 24.853  Millions$ 90.229  Millions
Roivant Sciences Ltd   0.27 $ 411.812  Millions$ 1,514.149  Millions
Aytu Biopharma inc   0.27 $ 14.485  Millions$ 53.906  Millions
Accustem Sciences Inc   0.27 $ 0.212  Millions$ 0.798  Millions
Eagle Pharmaceuticals inc   0.26 $ 61.392  Millions$ 231.780  Millions

Date modified: 2022-11-10T15:28:51+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HCYT's Profile

Stock Price

HCYT's Financials

Business Description

Fundamentals

Charts & Quotes

HCYT's News

Suppliers

HCYT's Competitors

Customers & Markets

Economic Indicators

HCYT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071